Jehanzeb Khan, MD
Pulmonary Disease · Schenectady, NYNPI 1770853426
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,700 of the $55,591 with a category attached, or 60.6%. GSK accounts for 70.9% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $34,523 and has fallen 92.5% since, to $2,579 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 647 payments — averaging $85.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$39K
- Intuitive Surgical$3K
- AstraZeneca$2K
- Johnson & Johnson$2K
- Boehringer Ingelheim$1K
- Pulmonx Corporation$1K
- plus $7K from 33 others
What the payments were for
- Speaking & faculty fees$33,70061%
- Travel & lodging$7,91214%
- Food & beverage$13,83225%
- Education$1130%
- Gifts$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 182 | $39,432 |
| Intuitive Surgical | 10 | $2,940 |
| AstraZeneca(2 entities) | 110 | $2,131 |
| Johnson & Johnson(2 entities) | 25 | $1,787 |
| Boehringer Ingelheim | 52 | $1,043 |
| Pulmonx Corporation | 3 | $1,005 |
| Harmony Biosciences LLC | 37 | $890 |
| Veran Medical Technologies, Inc. | 3 | $767 |
| Viiv Healthcare Company | 1 | $600 |
| Regeneron Healthcare Solutions, Inc. | 22 | $576 |
| Sanofi | 23 | $576 |
| Insmed, Inc. | 20 | $385 |
| AbbVie | 18 | $382 |
| Electromed, Inc. | 14 | $357 |
| Novartis | 16 | $333 |
| Amgen | 12 | $283 |
| Jazz Pharmaceuticals Inc. | 10 | $242 |
| Philips North America LLC | 12 | $210 |
| Grifols USA, LLC | 10 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $192 |
| Genentech USA, Inc. | 12 | $185 |
| Verona Pharma, Inc. | 8 | $173 |
| Pfizer | 7 | $137 |
| Inspire Medical Systems, Inc. | 1 | $119 |
| Galvanize Therapeutics, Inc | 1 | $107 |
| Merck | 4 | $89 |
| Actelion Pharmaceuticals US, Inc. | 3 | $66 |
| Mylan Specialty L.p. | 3 | $52 |
| Shionogi Inc | 2 | $45 |
| Viatris Specialty LLC | 2 | $44 |
| Circassia Inc. | 3 | $44 |
| Astellas Pharma US Inc | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Abbott | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$32,587
- ANORO$3,600
- Da Vinci Surgical System$2,757
- Monarch Platform$1,409
- CHARTIS CATHETER$1,005
- ZEPHYR ENDOBRONCHIAL VALVE$1,005
- ZEPHYR DELIVERY CATHETER$1,005
- PULMONX CHARTIS TABLET CONSOLE$1,005
- Spin$718
- Inspire$119
- ALIYA SYSTEM$107
- FASENRA$105
- SYMBICORT$105
How this compares
$55,591 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 429 | $391,514 |
| NucalaMepolizumab | 40 | $163,061 |
| TezspireTezepelumab-Ekko | 33 | $142,221 |
| Fasenra PenBenralizumab | 17 | $93,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $86,260 |
| Dupixent PenDupilumab | 17 | $62,947 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $46,948 |
| Dupixent SyringeDupilumab | 11 | $38,323 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $37,313 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $34,355 |
| Spiriva RespimatTiotropium Bromide | 14 | $19,803 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $15,537 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 264 | $14,695 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $7,592 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $39,432 | $659,242645 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $2,131 | $228,481116 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $1,043 | $54,15954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Schenectady
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.